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Abstract 
Objective: The objective of the study was to assess the relationship of depression at antiretroviral therapy 
(ART) initiation with mortality and clinical outcomes among Tanzanian women living with HIV. 
Design: We conducted a prospective cohort study of 1,487 women who initiated ART in Dar es Salaam, 
Tanzania. 
Methods: Symptoms of depression and anxiety were assessed using a Tanzanian adapted and validated 
version of the Hopkins Symptom Checklist (HSCL-25).  Participants attended monthly clinic visits during 
the first two years of ART and CD4 T-cell counts were assessed every four months. Proportional hazard 
models were used to assess the relationship of depression with mortality and clinical outcomes.  
Results: Symptoms consistent with depression were prevalent among 57.8% of women at ART initiation. 
After multivariate adjustment including social support and stigma, depression at ART initiation was 
associated with increased risk of mortality (HR: 1.92; 95% CI: 1.15-3.20; p=0.01) and incidence of severe 
anemia (hemoglobin <8.5 g/dL) (HR: 1.59; 95% CI: 1.07-2.37; p=0.02). Under the assumption of 
causality, we estimate 36.1% (95% CI: 13.6-55.1%) of deaths among the study cohort were attributable to 
depression and its consequences.   Depression was not significantly associated with trajectory of CD4 T-
cell reconstitution or the risk of immunologic failure (p-values >0.05). 
Conclusions: Elimination of depression may reduce mortality during the first two years of ART by one-
third in our study cohort. Randomized trials and rigorous implementation studies are needed to evaluate 
the individual- and population-level effects of integrated mental health interventions and HIV treatment 
approaches in resouce-limited settings. 
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Introduction 
Access to antiretroviral therapy (ART) has expanded rapidly in resource-limited settings during 
the last decade and in 2014 over 10 million people living with HIV (PLH) in sub-Saharan Africa were 
receiving treatment [1]. Despite marked increases in ART coverage, PLH initiating treatment in sub-
Saharan Africa continue to experience high rates of morbidity and mortality as compared to PLH in high-
income settings, particularly during the initial months of ART [2, 3]. In the Dar es Salaam, Tanzania HIV 
care and treatment program, adult men and women initiating ART have a 1-year mortality risk of 13.1% 
[4]. As a result, low-cost ART adjunct interventions are urgently needed to improve survival and quality 
of life for PLH in sub-Saharan Africa. In particular, treatment for depression may constitute one of the 
strategies to improve outcomes among PLH [5].  
The risk of depression is at least two-fold as great among PLH as compared to the general 
population in both high and low-income settings [6, 7]. Multiple observational studies in high income 
countries have linked depression to increased risk of HIV disease progression and mortality; however, 
studies examining the relationship in resource-limited settings are much more limited [8, 9]. The 
mechanisms underlying the relationship of depression with mortality among people living with HIV are 
multifactorial and include poorer adherence to ART and altered immune responses [8, 10]. To the best of 
our knowledge, no studies have examined the relationship of depression with mortality among PLH who 
have access to ART in a resource-limited setting. In one of the few studies, our research group determined 
Tanzanian pregnant women living with HIV reporting symptoms consistent with depression had 
significantly increased risk of HIV disease progression and mortality; however, this study was conducted 
prior to the availability of ART [11].  
 In order to address the paucity of data on the relationship of depression with mortality and clinical 
outcomes among individuals receiving ART in resource-limited settings, we present a prospective cohort 
study of adult women living with HIV who initiated ART in Dar es Salaam, Tanzania. In this study we 
first examine sociodemographic and biological factors associated with symptoms consistent with 
depression at ART initiation and then assess the prospective relationship of depression with mortality, 
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morbidity, and immunologic outcomes at the individual- and population-level. These analyses are 
intended to determine if symptoms of depression remain associated with poor clinical outcomes among 
women living with HIV in Tanzania in the era of ART as well as to inform the potential population-level 
impact of interventions to reduce the prevalence of depression among women in the ART program.  
Methods 
Study Population 
This prospective cohort study included women living with HIV who were enrolled in a 
randomized and double-blind clinical trial conducted in Dar es Salaam, Tanzania during 2006–2010. This 
trial examined the effect of daily oral supplements of B-complex, C, and E vitamins at high versus the 
standard recommended dietary allowances (RDA) on HIV disease progression  (Clinicaltrials.gov 
NCT00383669) [12]. There was no difference in mortality, morbidity, or immunologic outcomes between 
groups randomized to the multivitamin regimens [12].  Individuals were eligible for the trial if they were 
18 years of age or older, initiated ART at trial enrollment, and intended to reside in the city of Dar es 
Salaam for the next two years. Women who were pregnant or lactating were excluded from the study. At 
the time of the trial, PLH with World Health Organization (WHO) HIV disease stage IV, CD4 T-cell 
count <200 cells/µL, or with WHO HIV stage III disease and CD4 T-cell count <350 cells/µL were 
initiated on ART [13].  
 
Baseline Depression and Covariate Assessment 
At the trial enrollment visit which occurred at ART initiation, the Hopkins Symptom Checklist 
(HSCL-25) was administered to assess symptoms of depression and anxiety. The HSCL-25 includes a 10-
item anxiety scale and a 15-item depression scale [14]. We have previously validated the HSCL-25 
among Tanzanian women living with HIV against diagnosis of major depressive disorder by a trained 
psychiatrist using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition (DSM-IV) [15, 16]. Based on the validation study results, we define symptoms 
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consistent with depression as an average score >1.06 for 8 questions which had demonstrated 88% 
sensitivity and 89% specificity compared with a DSM-IV diagnosis of major depressive disorder [16].  
To measure functional dimensions of social support, a scale based on the Duke University–
University of North Carolina Functional Social Support Questionnaire was also administered [17].  
Women were then classified as having low social support if their total score was less than the 50th 
percentile. In order to assess enacted HIV stigma participants were asked if they had faced any of the 
following as a result of their HIV status: (1) excluded from a social gathering; (2) sent away/left by 
spouse, partner, or family; (3) gossiped, teased, insulted, sworn at; (4) lost respect or standing in family or 
community; (5) lost a job; (6) had property taken away; or (7) had her child taken away [18]. Participants 
were also asked if and to whom they had disclosed their HIV status. 
A full clinical examination was also conducted at the baseline trial visit and a structured interview 
was completed to collect information on demographic characteristics. Study physicians also performed a 
complete medical examination and assessed HIV disease stage in accordance with the WHO guidelines, 
and collected blood specimens. Absolute CD4 T-cell count (FACSCalibur flow cytometer, Becton 
Dickinson, San Jose, CA) and complete blood count (AcT5 Diff AL analyzer, Beckman Coulter, Miami, 
FL) were also determined. Height/weight measurements were obtained by trained research assistants 
using standardized procedures and calibrated instruments [12]. 
 
Follow-up Assessments and Outcome Definitions 
During the trial follow-up period	participants were followed at monthly clinic visits. Participants 
who missed a clinic visit were followed at home where relatives or neighbors were asked about vital 
status of the participant. At each follow-up visit, study physicians performed a clinical examination, 
assessed WHO HIV disease stage, and diagnosed and treated any illness per standard of care [13]. 
Pulmonary tuberculosis was diagnosed according to Tanzanian National Tuberculosis and Leprosy 
Programme guidelines [19]. Height and weight were measured by clinic study nurses at each follow-up 
clinic visit. Wasting was defined as a body mass index of <18.5 kg/m2 and weight loss of >10% from 
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baseline was based on the definition of HIV-related wasting [20]. Absolute CD4 T-cell count and a 
complete blood count were taken at clinic visits every 4 months. We analyzed two definitions of 
immunologic failure: (i) the Tanzanian national criteria of a CD4 T-cell count less than ART initiation 
CD4 count after at least 6 months of therapy and (ii) WHO 2006 definition of a CD4 T-cell count of 100 
cells/µl or less after at least 6 months on therapy [21, 22]. Severe anemia was defined as a hemoglobin 
concentration of <8.5 g/dL [23].  
 
Statistical Analysis 
 We first examined the cross-sectional association of sociodemographic and biologic factors 
associated with symptoms consistent with depression at ART initiation using binomial regression models 
in order to obtain risk ratio estimates [24, 25]. Variables included in this cross-sectional analysis included: 
age, marital status, education, having children, wealth tertile, engagement in an income generating 
activity, smoking status, body mass index (BMI), WHO HIV disease stage, social support, HIV disclosure 
and experience of stigma. In order to produce a parsimonious multivariate model, any variable with a p-
value <0.20 in univariate models was included in the final multivariate model.  
The prospective relationship of symptoms consistent with depression at ART initiation and 
mortality was investigated using proportional hazard models [26]. Proportional hazard models were also 
used to investigate the relationship of depression and first occurrence of pulmonary tuberculosis, oral 
thrush, severe anemia (hemoglobin <8.5 g/dL), wasting (BMI <18.5 kg/m2), >10% weight loss from ART 
initiation, and immunologic failure. For these morbidity outcomes, we excluded women who received a 
prevalent diagnosis of the event of interest at ART initiation. Confounders for all multivariate analyses 
were determined a priori by the study team based on potential associations with both depression and HIV 
treatment outcomes with the additional requirement that the variable was not a mediator of the 
relationship of interest. Confounders included in multivariate models included baseline age, marital 
status, presence of living children, education, wealth tertile, income generating activity, smoking status, 
CD4 count, WHO HIV disease stage, BMI, social support, HIV disclosure, experience of stigma due to 
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HIV status, and randomized multivitamin regimen (high dose or single dose RDA). In addition we present 
sensitivity analyses defining symptoms consistent with depression using the standard (initially validated 
in the US) cutoff of 1.75 [14].  
We then calculated the partial population-attributable risk percentage (PAR%) for depression 
[27]. Partial PAR%s were used to estimate the percent of deaths that would not have occurred in our 
study population if a hypothetical intervention eliminated depression, but other baseline risk factors for 
mortality did not change as a result of the intervention. All prevalence and effect sizes for other risk 
factors for death included in the multivariate model were assumed to remain constant in calculation of 
partial PAR%. 
The association of symptoms consistent with depression at ART initiation with CD4 T-cell 
reconstitution was analyzed using generalized estimating equations (GEE) with stepwise restricted cubic 
splines to account for nonlinearity in CD4 T-cell trajectories [28, 29]. Change in CD4 T-cell count 
between clinic visits was modeled as a longitudinal continuous outcome while depression, time since 
ART initiation, and confounders were included as explanatory variables. An m-dependent working 
correlation matrix (m = 1) was used. In order to assess the statistical significance of differences in CD4 T-
cell trajectory by depression at ART initiation, we included the interactions of depression with time post 
ART initiation and its splines and the statistical significance assessed using the robust score test.  
As an exploratory analysis we examined whether the association of depression with all outcomes 
varied within strata of social status and HIV disease severity variables including: social support, stigma, 
WHO HIV stage, and CD4 T-cell count. In proportional hazard models the likelihood ratio test was used 
to test statistical significance of interaction, while the robust score test was used in GEE analyses. 
Multiple imputation was used in multivariate models to account for missing data [30]. All p-values were 
2-sided and p<0.05 was considered statistically significant. Statistical analyses were performed using the 
SAS v 9.4 (SAS Institute Inc., Cary, NC, USA). 
 
Ethics 
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The study was approved by the institutional review boards of the Harvard School of Public Health, 
Muhimbili University of Health and Allied Sciences, Tanzania Food and Drugs Authority, and National 
Institute of Medical Research. 
 
Results 
 A total of 1,487 women initiating ART in the parent trial had the HSCL-25 administered at ART 
initiation. Socio-demographic, clinical, depression, disclosure, and stigma attributes of the cohort at ART 
initiation are presented in Table 1. At ART initiation, 859 women (57.8%) had prevalent symptoms 
consistent with depression utilizing the Tanzanian adapted and validated HSCL-25 cut-off. In 
Supplementary Table 1, we present a response summary of all individual HSCL-25 items. The most 
common HSCL-25 items endorsed with ‘at least a little’ were loss of sexual interest or pleasure (37.1%), 
feeling low in energy/slowed down (35.3%), worrying too much (34.4%), and blaming oneself about 
things (31.9%). Of note, 236 women (15.9%) reported they felt like ending their life ‘at least a little’. At 
ART initiation 122 women (8.2%) reported experience with HIV enacted stigma and 80 women (5.4%) 
had not disclosed their HIV status to anyone.  
   In Table 2 we present baseline factors associated with symptoms consistent with depression at 
ART initiation. In parsimonious multivariate models, women with low social support (< median level) 
had 1.32 times (95% CI: 1.32-1.21-1.45; p<0.01) the prevalence of depression at ART initiation as 
compared to those with high social support (≥ median level). The only other factor significantly 
associated with depression in multivariate models was experience of HIV enacted stigma. Women who 
reported experience with enacted stigma had 1.50 times (95% CI: 1.38-1.62; p<0.01) the prevalence of 
depression at ART initiation.  In sensitivity analyses utilizing the 1.75 score cutoff to define symptoms 
consistent with depression (US-validated), social support and enacted stigma remained significantly 
associated with depression with the addition of current smoking as a significant factor (Supplemental 
Table 2). 
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The median follow-up time post ART initiation for the cohort was 24.1 months (IQR: 15.7-35.1 
months), and during this period 80 deaths (5.4%) were recorded among the cohort of 1,487 women. At 
the end of the trial, vital status was unknown for 7.0% of participants and was similar for those with 
(7.1%) and those without symptoms of depression (6.8%). Table 3 shows the univariate and multivariate 
relationship of symptoms consistent with depression at ART initiation and mortality. Among women with 
symptoms of depression at ART initiation a total of 57 of 859 women (6.6%) died, while only 23 of 628 
women (3.7%) without symptoms of depression died. Multivariate analysis (including adjustment for 
stigma and social support) determined women with depression at ART initiation had 1.92 times (95% 
1.15-3.20; p=0.01) the hazard of mortality as compared to women without depression.  We estimate the 
percentage of death attributed to depression and its consequences (population attributable risk percent) in 
our study cohort was 36.1% (95% CI: 13.6-55.1%). We found no significant evidence of interaction for 
the depression and mortality relationship by social support, stigma, CD4 T-cell count, and WHO stage (p-
values for interaction >0.10).  In a sensitivity analysis, the magnitude of the relationship of symptoms 
consistent with depression as defined by the standard HSCL-25  score cutoff  of 1.75 remained consistent 
(HR: 1.94; 1.17-3.23; p=0.01) (Supplemental Table 3).  
Table 3 also presents the association of symptoms consistent with depression at ART initiation 
with morbidity and nutritional outcomes. Women with symptoms of depression had significantly 
increased hazard of incident severe anemia (HR: 1.59; 95% CI: 1.07-2.37; p=0.02). In addition, there was 
some indication that women with depression may also have increased risk of oral thrush (HR: 1.15; 0.84-
1.58; p=0.38) and wasting (HR: 1.22; 95% CI: 0.81-1.83; p= 0.34), but results were not statistically 
significant.  There was no significant evidence for interaction of any morbidity or nutrition association by 
any third variable (p-values for interaction >0.10).  Sensitivity analyses using the 1.75 score cutoff for 
depression determined similar magnitudes of association for morbidity associations (Supplemental Table 
3). 
A total of 1,335 women (90%) had two or more CD4 T-cell count measurements during the study 
follow-up period. As expected change in CD4 T-cell count post ART initiation was non-linear with 
10	
	
 
	
greater increases in CD4 T-cell count during the initial 6 months of treatment. Figure 1 presents the nearly 
identical trajectory of CD4 T-cell counts post ART initiation for women with symptoms of depression 
versus those without. There was no indication of a difference in mean CD4 T-cell counts at baseline (93 
vs. 112 cells/µL), 4 months (150 vs. 145 cells/µL), 8 months (321 vs. 331 cells/µL), 12 months (356 vs. 
353 cells/µL) and 16 months (396 vs. 391 cells/µL) for women with symptoms of depression as compared 
to those without, respectively (p-value for difference in trajectory =0.40). There was also no difference in 
CD4 trajectory by symptoms of depression status in multivariate models (p-value for difference in 
trajectory =0.38). We also found no significant relationship of symptoms of depression at ART initiation 
with immunologic failure using two standard definitions (Table 3). There was no significant evidence of 
interaction of any CD4 trajectory or immunologic failure relationship by any third variable (p-values for 
interaction >0.10) and there was no difference in associations using the 1.75 score cutoff to define 
symptoms consistent with depression (Supplemental Table 3 and Supplemental Figure 1). 
 
Discussion 
 In this study we found over half of Tanzanian women in our study population had symptoms 
consistent with depression at ART initiation. Low social support and experience of stigma were 
significant risk factors for depression while markers of HIV disease severity (CD4 T-cell count, WHO 
stage, BMI) had no significant relationship. Prospectively, women with symptoms consistent with 
depression at ART initiation had almost twice the risk mortality as well as incidence of severe anemia. In 
terms of potential population-level impact, we estimate that one-third of deaths in the cohort were 
attributed to depression and its consequences.  There was no difference in CD4 T-cell reconstitution 
trajectory or risk of immunologic failure during the first 2 years of ART by depression status.  
 At ART initiation we determined that over 50% of women living with HIV in urban Tanzania had 
symptoms consistent with depression at ART initiation. In a previous study of Tanzanian pregnant 
women living with HIV conducted in the same setting before the availability of ART, we found the 
prevalence of depression was 43% utilizing the same adapted HSCL-25 cut-off to define depression [11]. 
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As a result, the prospect of access to ART may not have resulted in reductions in the prevalence of 
depression among women in urban Tanzania. In a cross-sectional analysis we found only social support 
and enacted stigma were associated with prevalent symptoms consistent with depression. These findings 
are consistent with a growing number of studies in sub-Saharan Africa that have shown social support is a 
key, if not primary, determinant of depression risk and quality of life for individuals on ART [31-33]. Our 
results are partially in contrast to studies of combined male and female PLH populations in rural South 
Africa and Uganda which found strong relationships of low CD4 T-cell counts with increased risk of 
depression [32, 34]. The lack of an association of markers of HIV disease severity, including CD4 T-cell 
count and WHO HIV stage, with symptoms of depression in our study population of women in Tanzania 
initiating ART may indicate the determinants and magnitudes of risk for depression among PLH may 
vary by sex, setting, and duration of ART. Specifically, our study population of women initiating ART 
based on standardized treatment guidelines is by definition more homogenous in terms of HIV disease 
severity as compared to population-based studies and may be underpowered to detect moderate to small 
differences in CD4 T-cell count. In addition our cross-sectional analysis may be prone to selection bias by 
differences in care seeking behaviors for women with depression. 
 In prospective analyses, we found women reporting symptoms consistent with depression at ART 
initiation had almost twice the risk of mortality during the first 2 years of treatment as compared to 
women without depression. To our knowledge, this is the first study linking depression to mortality for a 
population with access to ART in a resource-limited setting. In our previous study of Tanzanian pregnant 
women living with HIV before availability of ART, women with depression had 2.65 times the risk of 
mortality as compared to those without depression [11]. Accordingly, in the presence of ART availability, 
depression remained strongly associated with mortality among Tanzanian women, but the magnitude of 
the association may be slightly smaller as compared to the pre-ART era; however, these conclusions 
cannot be directly drawn from this study due to differences in time and pregnancy status of participants. 
Studies in the US and Europe have also determined that PLH with depression were at increased risk of 
mortality and poor clinical outcomes both before and after the discovery of highly active antiretroviral 
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therapy [8, 35, 36]. A limitation of our study is that depression status was determined by a symptom 
checklist, which may lead to misclassification; however, we utilized a locally adapted version of the 
HSCL-25 with cut-off scores calibrated to the DSM-IV depression criteria to minimize potential bias and 
performed sensitivity analyses utilizing US-validated cutoffs. Nevertheless, potential non-differential 
misclassification of depression status would lead us to underestimate the magnitude of the true effect.  In 
addition, we only had data on symptoms of depression at ART initiation and future studies should 
examine the relationship of change in symptoms of depression over time with mortality and HIV 
treatment outcomes.  
The mechanisms underlying the relationship of depression and HIV mortality are potentially a 
combination of behavioral and biological factors. There is a large literature linking depression to 
decreased ART adherence in both high- and low-income settings [37, 38]. In a recent review of twenty 
three studies presenting data on depression and ART adherence in sub-Saharan Africa, the pooled 
probability of achieving ‘good’ adherence to ART was 55% lower among PLH with depressive symptoms 
[10]. Unfortunately, in the current study we did not have measures of ART adherence and as a result we 
were unable to examine adherence as a potential mediator of the relationship of depression with mortality. 
There is also growing evidence that depression can have deleterious effects on immune system function, 
particularly cell-mediated responses [39]. Several studies have found PLH with depression have 
decreased cytotoxic CD8+ T-cell counts and decreased number and function of natural killer (NK) cells, 
which may lead to decreased lysis of HIV-infected cells and increased viral replication [40, 41]. 
Accordingly, interventions which only promote ART adherence for individuals with depression may not 
completely reduce the excess mortality risk due to underlying immunologic deficits resulting from 
depression.  
 In the current study we found no significant association of depression at ART initiation with CD4 
T-cell reconstitution or risk of immunologic failure. Our findings are somewhat in contrast to prospective 
cohort studies in high-income settings which have found individuals with depression had poorer CD4 T-
cell and viral load outcomes on ART, but evidence in resource-limited settings is much more limited [42-
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44]. In a longitudinal study of Ethiopian PLH, each one unit increase in depression severity as measured 
by the Center for Epidemiological Studies Depression Scale (CES-D) questionnaire was associated with a 
10 cells/µL lower CD4 T-cell count at timepoints post ART initiation [45]. As a result, the contributions 
of biological and adherence mechanisms to the relationship of depression with CD4 T-cell reconstitution 
may also differ by sex, setting, and by duration of ART. ART adherence in also known to decrease over 
time and since our study examined the period immediately following ART initiation there may have been 
minimal variation in immunologic response by depression status [46]. As a result, we may have been 
underpowered to detect moderate to small differences in CD4 T-cell trajectory by depression status. 
Nevertheless, our CD4 T-cell trajectory and immunologic failure results may also be biased towards the 
null due to competing risk of death in our cohort. Women who died before 6 months of ART did not 
receive a follow-up CD4 T-cell count measurement eligible for determination of immunologic failure and 
therefore women who may have had the poorest CD4 T-cell trajectories were possibly excluded from our 
analyses. 
The combination of the high prevalence and strong risk of mortality associated with symptoms of 
depression among women starting ART in Tanzania suggest providing effective psychosocial 
interventions may have a large population-level impact on improving survival and quality of life. 
Assuming a causal relationship, we estimated eliminating depression may avert about one-third of deaths 
in our study population. Nevertheless, due to the observational nature of the study our population 
attributable risk estimate should be interpreted with caution due to potential for confounding and bias in 
risk estimates. Nevertheless, our findings provide support for future large scale intervention studies of 
depression prevention and treatment for women living with HIV in Tanzania and similar resource-limited 
settings.  
Cognitive behavioral therapy, interpersonal psychotherapy, and problem-solving therapy 
interventions have shown promise in terms of reducing depression among PLH; however, very few HIV 
programs have integrated mental health interventions into their routine ART services in resource-limited 
settings [5]. Our results strongly support randomized controlled trials and rigorous implementation 
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evaluations of integrated mental health programs are needed to determine the effect of depression 
interventions on early mortality and clinical outcomes among HIV-infected women starting ART in 
resource-limited settings. Additional studies of depression are also needed among HIV-infected adult 
men, adolescents, childrenm and pregnant women on ART. 
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Table 1. Characteristics of HIV-infected Tanzanian women (n=1,487) administered the HSCL-25 
at ART initiation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristic Frequency (%) 
Age (years)  
  <30  272 (18.3) 
   ≥30 and <40 743 (50.0) 
   ≥40 471 (31.7) 
   Missing 1 (0.1) 
Marital status  
   Married 457 (35.4) 
   Single 201 (15.6) 
   Divorced  333 (25.8) 
   Widow 299 (23.2) 
   Other 107 (7.2) 
Has at least one living child  
   Yes 1279 (87.2) 
   No 188 (18.8) 
Education  
   None/Primary 815 (54.8) 
   Secondary plus 484 (32.5) 
   Missing 188 (12.6) 
No income generating activity 525 (35.3) 
Report current smoking 31 (2.1) 
Report alcohol use in last 30 days 22 (1.5) 
CD4 T-cell count (cells/µL)  
   <50  284 (19.1)  
   ≥50 and <100 269 (18.1) 
   ≥100 and <200 569 (38.3) 
   ≥200 324 (21.8) 
   Missing 41 (2.8) 
WHO HIV disease stage   
   I/II 338 (22.7) 
   III 888 (59.7) 
   IV 150 (10.1) 
   Missing 111 (7.5) 
Body mass index (kg/m2)  
   <18.5 355 (23.9)  
   ≥ 18.5 and <25.0 855 (57.5) 
   ≥ 25.0  277 (18.6) 
Antiretroviral regimen  
   d4T, 3TC, NVP 895 (6.2) 
   d4T, 3TC, EFV 150 (10.1) 
   AZT, 3TC, NVP 132 (8.9) 
   AZT, 3TC, EFV 309 (20.8) 
   Missing 1 (0.1) 
Symptoms consistent with depression 859 (57.8) 
Has told no one of HIV status 80 (5.4) 
Experienced stigma due to HIV status 122 (8.2) 
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Table 2. Risk factors for symptoms consistent with depression at ART initiation among HIV-
infected Tanzanian women (n=1,487). 
Characteristic 
No. depressed / 
Total (%) 
Univariate  RR 
(95% CI) p-value 
Multivariate  RR    
(95% CI) p-value 
Age (years)      
  <30  159 / 272 (58.5)  Ref.    
  ≥30 and <40 438 / 743 (59.0)  1.01 (0.90-1.13)    
  ≥40 261 / 471 (55.4) 0.95 (0.83-1.08) 0.20a   
Marital status      
   Married  254 / 457 (55.6) Ref.  Ref.  
   Single 126 / 201 (62.7)  1.10 (0.97-1.25) 0.13 1.09 (0.96-1.23) 0.20 
   Divorced  186 / 333 (55.9) 0.98 (0.87-1.11) 0.78 0.95 (0.85-1.07) 0.40 
   Widow 182 / 299 (60.9) 1.07 (0.96-1.20) 0.23 1.03 (0.92-1.15) 0.65 
Has children      
   Yes 123 / 208 (59.1) Ref.    
    No 736 / 1279 (57.5) 0.95 (0.84-1.07) 0.66   
Education      
   None/Primary 457 / 815 (56.1)  0.91 (0.83-1.00) 0.05 0.93 (0.85-1.02) 0.12 
   Secondary plus 298 / 484 (61.6) Ref.  Ref.   
Wealth tertile      
   Poorest tertile 220 / 394 (55.8) 0.97 (0.87-1.09) 0.55a   
   Middle tertile 335 / 569 (58.9) 1.03 (0.93-1.14)    
   Richest tertile 281 / 490 (57.4) Ref.    
Income generating activity      
  Yes  558 / 962 (58.0) Ref.    
  No  301 / 525 (57.3) 0.99 (0.90-1.09) 0.85   
Smoking       
  Current smoker 20 / 31 (64.5) 1.12 (0.86-1.46) 0.41   
  Not current smoker 839 / 1456 (57.6) Ref.    
CD4 T-cell count (cells/µL)      
   <50  171 / 284 (60.2)  1.08 (0.94-1.23) 0.58a   
   ≥50 and <100 146 / 268 (54.3) 0.97 (0.84-1.12)    
   ≥100 and <200 336 / 569 (59.1) 1.06 (0.94-1.19)    
   ≥200 181 / 324 (55.9) Ref.    
WHO HIV disease stage       
   I/II 188 / 338 (55.6)  Ref.  Ref.  
   III 510 / 888 (57.4) 1.03 (0.92-1.15)  1.01 (0.91-1.12)  
   IV 94 / 150 (62.7)  1.13 (0.96-1.32) 0.16a 1.08 (0.92-1.26) 0.41a 
Body mass index (kg/m2)      
   <18.5 213 / 355 (60.0)  1.04 (0.94-1.15) 0.47   
   ≥18.5 and <25.0 494 / 855 (57.8) Ref.    
   ≥25.0  152 / 277 (54.9)  0.95 (0.84-1.07) 0.41   
Social support      
  Low <50th percentile  481 / 714 (67.4) 1.38 (1.26-1.50) <0.01 1.32 (1.21-1.45) <0.01 
  High ≥50th percentile 378 / 773 (48.9) Ref.  Ref.  
HIV status disclosure      
  Told no one of HIV status 54 / 80 (67.5) 1.18 (1.01-1.38) 0.04 1.14 (0.98-1.33) 0.10 
  Disclosed HIV status  805 / 1407 (57.2) Ref.  Ref.   
Enacted stigma      
  Experienced stigma 110 / 122 (90.2) 1.64 (1.52-1.77) <0.01 1.50 (1.38-1.62) <0.01 
  No experience of stigma  749 / 1365 (54.9) Ref.  Ref.  
a p-value for trend 
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Table 3. Association of symptoms consistent with depression at HAART initiation with incidenta 
mortality, morbidity, weight loss, severe anemia, and immunologic failure among HIV-infected 
Tanzanian women (n=1,487).  
 
aExcluding individuals who had event of interest at baseline 
bAdjusted for age (<30, ≥30 and <40, and ≥40 years), marital status (married, single, divorced, widowed), 
education (none/primary vs. secondary plus), has children (yes vs. no) wealth tertile, income generating 
activity (yes vs. no), smoking status (current smoker vs. not current smoker), CD4 count (<50, ≥50 and 
<100, ≥100 and <200, and ≥200 cells/µL), WHO HIV disease stage (I/II, III, IV), body mass index 
(<18.5, ≥18.5 and <25.0, ≥25.0 kg/m2), social support (<50th percentile vs. ≥50th percentile), HIV 
disclosure (told no one vs. disclosed status), experience stigma due to HIV status (yes vs. no) and 
randomized multivitamin regimen (high dose or single RDA). Wasting and weight loss multivariate 
models not adjusted for baseline BMI.  
 
Outcome 
Events / Total 
(%) 
Crude HR           
(95% CI) p-value 
Multivariateb             
RR (95% CI) 
p-
value 
Mortality      
   Depression 57 / 859 (6.6) 1.84 (1.14-2.99) 0.01 1.92 (1.15-3.20) 0.01 
   No Depression 23 / 628 (3.7) Ref.   Ref.   
Pulmonary tuberculosisa      
   Depression 38 / 778 (4.9) 0.74 (0.47-1.17) 0.20 0.77 (0.47-1.25) 0.29 
   No Depression 35 / 576 (6.1) Ref.   Ref.   
Oral thrusha      
   Depression 119 / 857 (13.9) 1.20 (0.89-1.62) 0.24 1.15 (0.84-1.58) 0.38 
   No Depression 66 / 626 (10.5) Ref.  Ref.   
Wasting (BMI <18.5 kg/m2)a      
   Depression 72 / 642 (11.2) 1.37 (0.93-2.01) 0.11 1.22 (0.81-1.83) 0.34 
   No Depression 40 / 442 (8.3) Ref.  Ref.   
Weight loss >10% from 
HAART initiation 
     
   Depression 188 / 859 (21.9) 1.19 (0.95-1.50) 0.14 1.05 (0.83-1.35) 0.67 
   No Depression 119 / 628 (19.0) Ref.  Ref.   
Severe Anemia (Hb <8.5 
g/dL)a 
     
   Depression 80 / 606 (13.2) 1.57 (1.075-2.30) 0.02 1.59 (1.07-2.37) 0.02 
   No Depression 40 / 454 (8.8) Ref.  Ref.  
Immunologic failurec defined 
as a CD4 T-cell count <100 
cells/µL after at least 6 month 
of ART  
     
   Depression 28 / 774 (3.6) 0.94 (0.54-1.64) 0.82 1.01 (0.56-1.80) 0.99 
   No Depression 22 / 579 (3.8) Ref.   Ref.  
Immunologic failure defined as 
a CD4 T-cell count after at 
least 6 months of ART less 
than initiation CD4 count 
     
   Depression 53 / 774  (6.9) 0.92 (0.62-1.38) 0.68 0.84 (0.55-1.29) 0.43 
   No Depression 43 / 579 (7.4) Ref.   Ref.  
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FIGURE TITLES 
 
Figure 1. Absolute CD4 T-cell count trajectory after ART initiation for HIV-infected Tanzanian women 
with symptoms consistent with depression (solid line for mean CD4 T-cell count and shaded cloud for 
95% confidence interval) and without (dotted line for mean CD4 T-cell count and hash-dot lines for 95% 
confidence interval). 
 
